194 related articles for article (PubMed ID: 29275295)
1. EZH2 Overexpression as a Useful Prognostic Marker for Aggressive Behaviour in Thyroid Cancer.
Masudo K; Suganuma N; Nakayama H; Oshima T; Rino Y; Iwasaki H; Matsuzu K; Sugino K; Ito K; Kondo T; Nakamura Y; Yoshihara M; Masuda M; Miyagi Y
In Vivo; 2018; 32(1):25-31. PubMed ID: 29275295
[TBL] [Abstract][Full Text] [Related]
2. Comparing outcomes in poorly-differentiated versus anaplastic thyroid cancers treated with radiation: a surveillance, epidemiology, and end results analysis.
Arora S; Christos P; Pham A; Desai P; Wernicke AG; Nori D; Chao KS; Parashar B
J Cancer Res Ther; 2014; 10(3):526-30. PubMed ID: 25313732
[TBL] [Abstract][Full Text] [Related]
3. Recurrence and Survival After Gross Total Removal of Resectable Undifferentiated or Poorly Differentiated Thyroid Carcinoma.
Lee DY; Won JK; Choi HS; Park do J; Jung KC; Sung MW; Kim KH; Hah JH; Park YJ
Thyroid; 2016 Sep; 26(9):1259-68. PubMed ID: 27412715
[TBL] [Abstract][Full Text] [Related]
4. Changes of Clinicopathologic Characteristics and Survival Outcomes of Anaplastic and Poorly Differentiated Thyroid Carcinoma.
Lee DY; Won JK; Lee SH; Park DJ; Jung KC; Sung MW; Wu HG; Kim KH; Park YJ; Hah JH
Thyroid; 2016 Mar; 26(3):404-13. PubMed ID: 26541309
[TBL] [Abstract][Full Text] [Related]
5. Enhancer of zeste homolog 2 overexpression has a role in the development of anaplastic thyroid carcinomas.
Borbone E; Troncone G; Ferraro A; Jasencakova Z; Stojic L; Esposito F; Hornig N; Fusco A; Orlando V
J Clin Endocrinol Metab; 2011 Apr; 96(4):1029-38. PubMed ID: 21289264
[TBL] [Abstract][Full Text] [Related]
6. Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing.
Duan H; Li Y; Hu P; Gao J; Ying J; Xu W; Zhao D; Wang Z; Ye J; Lizaso A; He Y; Wu H; Liang Z
Histopathology; 2019 Dec; 75(6):890-899. PubMed ID: 31230400
[TBL] [Abstract][Full Text] [Related]
7. Enhancer of zeste homologue 2 (EZH2) expression in synovial sarcomas as a promising indicator of prognosis.
Yalçınkaya U; Uğraş N; Özgün G; Ocakoğlu G; Deligönül A; Çetintaş SK; Bilgen MS
Bosn J Basic Med Sci; 2017 Nov; 17(4):302-308. PubMed ID: 28738014
[TBL] [Abstract][Full Text] [Related]
8. Expression profile of biomarkers altered in papillary and anaplastic thyroid carcinoma: Contribution of Tunisian patients.
Fourati A; El Amine O; Ben Ayoub W; Cherni I; Goucha A; El May MV; Gamoudi A; El May A
Bull Cancer; 2017 May; 104(5):433-441. PubMed ID: 28185633
[TBL] [Abstract][Full Text] [Related]
9. Modulation of EZH2 Activity Induces an Antitumoral Effect and Cell Redifferentiation in Anaplastic Thyroid Cancer.
de Mello DC; Saito KC; Cristovão MM; Kimura ET; Fuziwara CS
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175580
[TBL] [Abstract][Full Text] [Related]
10. Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.
Nikitski AV; Rominski SL; Condello V; Kaya C; Wankhede M; Panebianco F; Yang H; Altschuler DL; Nikiforov YE
Thyroid; 2019 Oct; 29(10):1425-1437. PubMed ID: 31298630
[No Abstract] [Full Text] [Related]
11. Expression of cancer stem cell markers and epithelial-mesenchymal transition-related factors in anaplastic thyroid carcinoma.
Jung CW; Han KH; Seol H; Park S; Koh JS; Lee SS; Kim MJ; Choi IJ; Myung JK
Int J Clin Exp Pathol; 2015; 8(1):560-8. PubMed ID: 25755746
[TBL] [Abstract][Full Text] [Related]
12. Validation of EZH2 Inhibitor Efficiency in Anaplastic Thyroid Carcinoma Cell Lines.
Nakayama H; Saito N; Kasajima R; Suganuma N; Rino Y; Masudo K; Yamazaki H; Toda S; Sekihara K; Iwasaki H; Hoshino D
Anticancer Res; 2023 Mar; 43(3):1073-1077. PubMed ID: 36854530
[TBL] [Abstract][Full Text] [Related]
13. FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale.
Adam P; Kircher S; Sbiera I; Koehler VF; Berg E; Knösel T; Sandner B; Fenske WK; Bläker H; Smaxwil C; Zielke A; Sipos B; Allelein S; Schott M; Dierks C; Spitzweg C; Fassnacht M; Kroiss M
Front Endocrinol (Lausanne); 2021; 12():712107. PubMed ID: 34475850
[TBL] [Abstract][Full Text] [Related]
14. Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma.
Grabellus F; Nagarajah J; Bockisch A; Schmid KW; Sheu SY
Clin Nucl Med; 2012 Feb; 37(2):121-7. PubMed ID: 22228332
[TBL] [Abstract][Full Text] [Related]
15. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas.
Kidani K; Osaki M; Tamura T; Yamaga K; Shomori K; Ryoke K; Ito H
Oral Oncol; 2009 Jan; 45(1):39-46. PubMed ID: 18619895
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas.
Wang Y; Chen Y; Geng H; Qi C; Liu Y; Yue D
Tumour Biol; 2015 Sep; 36(9):7159-66. PubMed ID: 25877750
[TBL] [Abstract][Full Text] [Related]
17. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
[TBL] [Abstract][Full Text] [Related]
18. EZH2 expression is a prognostic factor in childhood intracranial ependymoma: a Canadian Pediatric Brain Tumor Consortium study.
Li AM; Dunham C; Tabori U; Carret AS; McNeely PD; Johnston D; Lafay-Cousin L; Wilson B; Eisenstat DD; Jabado N; Zelcer S; Silva M; Scheinemann K; Fryer C; Hendson G; Fotovati A; Hawkins C; Yip S; Dunn SE; Hukin J
Cancer; 2015 May; 121(9):1499-507. PubMed ID: 25586788
[TBL] [Abstract][Full Text] [Related]
19. Long noncoding RNA PVT1 modulates thyroid cancer cell proliferation by recruiting EZH2 and regulating thyroid-stimulating hormone receptor (TSHR).
Zhou Q; Chen J; Feng J; Wang J
Tumour Biol; 2016 Mar; 37(3):3105-13. PubMed ID: 26427660
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]